Telesis Bio, Inc.

TBIO

US1920031010

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-26 pm EDT			5-day change	1st Jan Change
0.3184 ^USD	-0.93%		+3.04%	-20.20%

Apr. 18	Telesis Bio, Inc. Announces Appointment of Eric Esser to the Board of Directors	CI
Apr. 18	Telesis Bio Inc. Announces Strategic Focus on Game-Changing Gibson Sola Enzymatic DNA Synthesis Platform and BioXp mRNA Solutions	CI

Telesis Bio, Inc. announced that it has received $28 million in funding from Novalis Capital Partners LLC, Northpond Ventures, LLC, BroadOak Capital Partners LLC, Investment Arm and another investor

June 04, 2023

On June 5, 2023, Telesis Bio, Inc. closed the transaction.

Latest news about Telesis Bio, Inc.

Telesis Bio, Inc. Announces Appointment of Eric Esser to the Board of Directors	Apr. 18	CI
Telesis Bio Inc. Announces Strategic Focus on Game-Changing Gibson Sola Enzymatic DNA Synthesis Platform and BioXp mRNA Solutions	Apr. 18	CI
Telesis Bio, Inc. Announces Chief Executive Officer Changes	Apr. 18	CI
Earnings Flash (TBIO) TELESIS BIO Reports Q4 Revenue $7M	Mar. 28	MT
Telesis Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 28	CI
Telesis Bio, Inc. Reports Impairment Charges for the Fourth Quarter Ended December 31, 2023	Mar. 28	CI
Telesis Bio, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 26	CI
Earnings Flash (TBIO) TELESIS BIO Posts Q3 Revenue $5.6M, vs. Street Est of $7.4M	Nov. 13	MT
Telesis Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Telesis Bio, Inc. Provides Earnings Guidance for 2023	Nov. 13	CI
Telesis Bio, Inc. Announces Default of 2022 Term Loan Agreement	Nov. 09	CI
Telesis Bio, Inc. Announces Board Changes	23-09-22	CI
Telesis Bio Names William Kullback as CFO	23-08-29	MT
Telesis Bio Inc. Appoints William J. Kullback Chief Financial Officer	23-08-29	CI
North American Morning Briefing : Stock Futures -2-	23-08-14	DJ
Telesis Bio Downgraded by KeyBanc Over 'Tepid' Biopharma Spending, 'Significant Dilution'	23-08-11	MT
KeyBanc Downgrades Telesis Bio to Sector Weight From Overweight, Cites 'Limited Top-Line Visibility' Amid 'Tepid Biopharma Spending Environment'	23-08-11	MT
Transcript : Telesis Bio, Inc., Q2 2023 Earnings Call, Aug 10, 2023	23-08-10
Earnings Flash (TBIO) TELESIS BIO Posts Q2 Revenue $8.7M, vs. Street Est of $8.6M	23-08-10	MT
Telesis Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Top Premarket Gainers	23-06-12	MT
Telesis Bio, Inc. Appoints Paul Meister as Director	23-06-09	CI
Telesis Bio, Inc. announced that it has received $28 million in funding from Novalis Capital Partners LLC, Northpond Ventures, LLC, BroadOak Capital Partners LLC, Investment Arm and another investor	23-06-04	CI
Telesis Bio Secures $28 Million Preferred Equity Financing	23-06-01	MT
Telesis Bio, Inc. announced that it expects to receive $28 million in funding from Novalis Capital Partners LLC, Northpond Ventures, LLC, BroadOak Capital Partners LLC, Investment Arm and another investor	23-05-30	CI

Telesis Bio Inc. is a provider of ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) solutions. The Company provides automated multi-omic and synthetic biology solutions focused on providing applications to enable researchers to rapidly and reproducibly build or write high-quality synthetic DNA and messenger Ribonucleic Acid (mRNA) and short oligonucleotides that are ready to use in many downstream synthetic biology enabled markets. Its BioXp system consolidates, automates, and optimizes the entire synthesis, cloning and amplification workflow. Its on-market and its planned solutions include BioXp 3250 system, BioXp 9600 system, BioXp portal, BioXp De Novo kits, BioXp Select kits, BioXp Next Generation Sequencing kits, Benchtop reagents and Custom Gibson Short Oligo Ligation Assembly (SOLA) enzymatic DNA synthesis (EDS) solutions. BioXp Select kits offer customers the ability to use non-Telesis Bio DNA while using the BioXp system to perform synthetic biology workflow applications.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-05-07 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.3184

Average target price

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
TELESIS BIO, INC.	-20.20%	9.58M
THERMO FISHER SCIENTIFIC	+8.07%	219B
DANAHER CORPORATION	+6.59%	183B
INTUITIVE SURGICAL, INC.	+11.26%	133B
BOSTON SCIENTIFIC CORPORATION	+26.57%	108B
SIEMENS HEALTHINEERS AG	+0.65%	63.06B
EDWARDS LIFESCIENCES CORPORATION	+13.35%	52.02B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-0.62%	48.2B
AGILENT TECHNOLOGIES, INC.	-0.93%	40.37B
GE HEALTHCARE TECHNOLOGIES INC.	+11.54%	39.35B

Other Advanced Medical Equipment & Technology

Telesis Bio, Inc.

Equities

TBIO

US1920031010

Advanced Medical Equipment & Technology

Telesis Bio, Inc. announced that it has received $28 million in funding from Novalis Capital Partners LLC, Northpond Ventures, LLC, BroadOak Capital Partners LLC, Investment Arm and another investor

Latest news about Telesis Bio, Inc.

Chart Telesis Bio, Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Advanced Medical Equipment & Technology